Reports Q4 revenue $9.35B, consensus $8.93B. “2023 was a year of tremendous achievement for Lilly, which delivered life-changing medicines to more patients than ever before resulting in strong revenue growth,” said David A. Ricks, Lilly’s chair and CEO. “We advanced our pipeline of new medicines for serious diseases and created new partnerships and innovative ways of collaborating to add to that pipeline. Lilly invested in the quality, reliability and resilience of our supply chain with new advanced manufacturing plants and lines in the U.S. and in Europe. Entering 2024, we remain focused on the opportunity in front of us, to help solve some of the most challenging healthcare problems in the world and make life better for millions of patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly Stock: All Eyes on Earnings This Week — Here’s What J.P. Morgan Expects
- Is LLY a Buy, Before Earnings?
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- Oppenheimer biotech/biopharma analysts hold analyst/industry conference call